Publication
MMP9 Knockout by CRISPR-Cas9 Reduces Bladder Cancer Malignancy But Does Not Synergize With BCG and Anti-PD-L1 in an Orthotopic Mouse Model.
Juliana Alves de Camargo, Maria Carolina Lee, Milena Monteiro de Souza, Luana Pereira da Silva, Giovanna Caetano Vilas Boas, Karina Serafim da Silva, Carolina Mie Mioshi, Ruan Cesar Aparecido Pimenta, Patrícia Candido, Iran Amorim da Silva, Ericka Barbosa Trarbach, Katia Ramos Moreira Leite, William Carlos Nahas, Sabrina Thalita Dos Reis
- Source
- PubMed
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260911-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Bladder cancer (BC) is the 10th most common cancer worldwide, accounting for approximately 5% of new cases. Several factors contribute to tumor progression, including increased MMP9. Recently, CRISPR-Cas9 and immunotherapy have offered high specificity for treatments; therefore, we edited MMP9…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Bladder Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available